Gitnux/Report 2026

Biomaterials Industry Statistics

The global biomaterials market is estimated at $274.6 billion in 2026, explore the figures behind growth, companies, and technology trends.
154Statistics
57Sources
11Sections
1Visuals
31mRead
Biomaterials Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The biomaterials industry at a glance

The global biomaterials market is estimated at $274.6 billion in 2026, with demand supported by implantable devices, tissue regeneration, and advanced medical-material applications.

$274.6B[45]
Global market size, 2026
17.3%[45]
Forecast CAGR, 2026–2033
38.1%[45]
North America share, 2025
$836.5B[45]
Projected market size, 2033
Market size
Grand View Research estimates the global biomaterials market at $237.0 billion in 2025 and $274.6 billion in 2026. Other market researchers publish materially different estimates because market definitions vary across implantable materials, medical devices, tissue-engineering products, and adjacent biomaterial applications.[45][46]
Forecast & CAGR
The market is forecast to reach $836.5 billion by 2033, implying a 17.3% CAGR from 2026 to 2033, according to Grand View Research. Straits Research forecasts a lower 13.48% CAGR from 2026 to 2034, illustrating the range of published outlooks.[45][46]
Market share & regions
North America held the largest regional share at 38.1% of global biomaterials revenue in 2025, according to Grand View Research. Asia-Pacific is identified as a major growth region, supported by expanding healthcare infrastructure, biotechnology investment, and demand for advanced treatments.[45][35]
Segmentation
The industry is commonly segmented by material type, including natural, metallic, polymer, and ceramic biomaterials, and by application, including cardiovascular, orthopedic, dental, plastic-surgery, wound-healing, tissue-engineering, and neurological uses. Grand View Research identifies natural, metallic, and polymer materials and cardiovascular, orthopedic, and plastic-surgery applications among its principal categories.[45][46]
Key players & concentration
No reliable public source reviewed provides a standardized global concentration ratio or combined market share for leading biomaterials companies. The market includes specialist biomaterial manufacturers, orthopedic and dental-device companies, medical-coatings suppliers, and diversified medical-device groups.[45][47]
Trends, drivers & challenges
Growth is being supported by musculoskeletal disease, chronic conditions, implant demand, regenerative medicine, 3D-printed biomaterials, and improved healthcare infrastructure. Key challenges include demonstrating long-term biocompatibility, managing degradation and wear, meeting regulatory requirements, and controlling manufacturing and clinical-development costs.[45][48]
M&A
Biomaterials M&A remained focused on specialist orthopedic and regenerative-medicine platforms. In October 2025, Heraeus Medical acquired INNOTERE, adding resorbable calcium-phosphate biomaterials and 3D-printed bone-substitution products; in March 2025, Novo Holdings and TA Associates entered a shared-control investment in Biocomposites, whose products are used in more than one million procedures annually.[47]
Regulation
In the United States, the FDA evaluates the biocompatibility of the finished medical device, including its materials, processing, sterilization, contact type, and duration of exposure. FDA’s September 2023 guidance incorporates risk-based assessment, chemical evaluation, and specific considerations for absorbable, in-situ polymerizing, submicron, and nanotechnology-containing materials.[48]
Latest news
The latest biomaterials-specific transaction identified in the reviewed sources was Heraeus Medical’s October 21, 2025 acquisition of INNOTERE. The deal expanded Heraeus Medical’s orthopedic portfolio with resorbable biomaterials for bone regeneration, including calcium-phosphate products and a 3D-printing-based product line.[47]

02 Ranking

Top 10 Companies in the Biomaterials Industry

The leading companies in the biomaterials industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 11, 2026 · Next review December 11, 2026

Verdict

NatureWorks stands out for Ingeo PLA biopolymers for packaging and fibers because it manufactures Ingeo PLA biopolymers for packaging and fibers, while Novamont focuses on MATER-BI compostable bioplastics since it is a recognized producer of MATER-BI compostable bioplastics.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in PLA biopolymers

    NatureWorks

    US

    Ranked #1 · 9.2 · PLA biopolymers

    Why we picked it: It supplies PLA biopolymers under the Ingeo brand used across packaging and fiber applications.

    See in ranking ↓Visit natureworksllc.com ↗

  2. Leader in compostable starch biopolymers

    Novamont

    IT

    Ranked #2 · 9.0 · Compostable starch biopolymers

    Why we picked it: Its MATER-BI compostable bioplastics sit in the compostable starch-based materials segment.

    See in ranking ↓Visit novamont.com ↗

  3. Leader in PHA biopolymers

    CJ Biomaterials

    US

    Ranked #3 · 8.9 · PHA biopolymers

    Why we picked it: Its Indonesia manufacturing supports PHA biopolymer supply for packaging and fiber use.

    See in ranking ↓Visit cjbiomaterials.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the biomaterials industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

NatureWorks

PLA biopolymers · US

9.2
2

Novamont

Compostable starch biopolymers · IT

9.0
3

CJ Biomaterials

PHA biopolymers · US

8.9
4

TotalEnergies Corbion

PLA biopolymers · NL

8.9
5

Corbion

Resorbable medical polymers · NL

8.7
6

BASF

Bio-based polymers and medical-grade materials · DE

8.7
7

Toray Industries

Advanced polymers and medical biomaterials · JP

8.7
8

PolyNovo

Bioresorbable polymers for wound care · AU

8.6
9

Kaneka

PHA biopolymers and medical biomaterials · JP

8.5
10

Covestro

High-performance polymers for healthcare and bio-based materials · DE

8.2

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 11, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 11). Top 10 companies in the biomaterials industry. In Biomaterials Industry Statistics. Gitnux. https://gitnux.org/biomaterials-industry-statistics/#top-companies

report visual · Comparison

Global bioplastics production capacity by region

Asia holds the largest share at 57.4%.

Asia57.4%
North America18.4%
Europe12.3%
South America11.2%
Australia/Oceania0.4%
source-verifiedresearchgate.net

04 Statistics

Technology & Innovation

We see broad adoption of analytics and automation-adjacent practices in adjacent chemical sectors, including 68% AI adoption among EII businesses in 2024.

Digital Transformation in the chemicals and materials sector (sector benchmark)

  • Across European chemical subindustries, 65% of companies viewed digitalization as an opportunity that would significantly impact their activities in 2024.[1]
  • Among ASUG chemicals-industry members, 57% identified moving to SAP S/4HANA as a top focus area in 2025.[2]
  • Among ASUG chemicals-industry members, 46% ranked automation among their leading technology focus areas in 2025.[2]
  • Among EII businesses, 68% reported adopting AI in 2024, with an estimated 10% productivity increase.[1]

Technology Adoption in the chemicals and materials sector (sector benchmark)

  • Among chemicals organizations surveyed by IBM, 49% had implemented AI for production planning and scheduling in 2025.[3]
  • Among chemicals organizations surveyed by IBM, 49% had implemented AI for quality inspection or defect detection in 2025.[3]
  • Among chemicals organizations surveyed by IBM, 53% had implemented AI for real-time process control and optimization in 2025.[3]
  • Among chemicals organizations surveyed by IBM, 45% had implemented AI for supply-chain optimization in 2025.[3]

Cloud Computing in the chemicals and materials sector (sector benchmark)

  • Among EII businesses, 52% reported increased productivity from cloud computing in 2024, while 46% reported no change.[1]
  • Across chemical-sector companies surveyed by Arthur D. Little and Cefic, more than 35% had at least partially migrated to cloud computing in 2023.[4]
  • Across chemical-sector companies surveyed by Arthur D. Little and Cefic, 15% planned to migrate to cloud computing in coming years in 2023.[4]
  • Among EII businesses, 2% reported decreased productivity from cloud computing in 2024.[1]

Big Data in the chemicals and materials sector (sector benchmark)

  • Among EII businesses, 48% reported increased productivity from big data in 2024.[1]
  • Among ASUG chemicals-industry members, 49% cited gaining actionable insights from data and analytics as a current challenge in 2025.[2]
  • Among EII businesses, 6% reported decreased productivity from big data in 2024.[1]
  • Among EII businesses, 44% reported no productivity change from big data in 2024.[1]

IoT in the chemicals and materials sector (sector benchmark)

  • Among EII businesses, 44% reported increased productivity from IoT in 2024.[1]
  • Across 23 European countries, close to one-third of manufacturing firms used IoT in 2021.[5]
  • Among EII businesses, 56% reported no productivity change from IoT in 2024.[1]
  • Across European countries, 29% of firms used IoT on average in 2021.[5]

Innovation in the biomaterials industry

  • 2,100+ grants had been awarded to biomaterials-sector projects by 2025.[6]
  • 3,300+ companies operate in the global biomaterials sector, according to a 2025 industry database.[6]
  • 73,000+ patents had been registered in the biomaterials sector by 2025, with more than 11,000 applicants involved.[6]
  • 470+ startups operate in the biomaterials sector, including 260 early-stage startups and 160 companies involved in mergers and acquisitions, in 2025.[6]
  • 11.98% was the annual growth rate recorded for the biomaterials sector in the 2025 industry database.[6]
  • 4,000+ funding rounds supported more than 800 biomaterials companies in the 2025 industry database.[6]

05 Statistics

Data & Analytics

Data quality and measurement show up as operational constraints, including 42% of manufacturers verifying manufacturing-data accuracy and quality in 2026.

Data analytics in the biomaterials industry

  • Corbion states that its life-cycle assessments are peer reviewed under ISO 14040, ISO 14044 and ISO 14067 to compare products and support new-product decisions.[7]
  • Amcor completed 1,683 ASSET life-cycle assessments in fiscal 2023 across its packaging portfolio.[8]

Data Quality in the chemicals and materials sector (sector benchmark)

  • 49% of supply-management organizations rated their data quality as good or excellent in 2024, based on an Institute for Supply Management survey.[9]
  • 89% of manufacturers said data use improved their decision-making processes in 2026, across the surveyed manufacturing sector.[10]
  • 42% of manufacturers had a process to verify manufacturing-data accuracy and quality in 2026, while 51% did not.[10]
  • 44% of companies in the manufacturing survey reported AI-project failures caused by poor data quality in 2025, across surveyed manufacturers.[11]
  • 80% of manufacturers reported a measured value for their operational data in 2026, across the surveyed manufacturing sector.[10]
  • 67% of supply-management organizations said their data quality was better or significantly better than two years earlier in 2024.[9]

Data Governance in the chemicals and materials sector (sector benchmark)

  • 52% of global chemical companies had established performance management or KPIs around digital supply chains in 2022.[12]
  • 61% of supply-management organizations had a dedicated data-governance function in 2024, based on a survey of more than 121 respondents.[9]
  • 46% of GCC chemical companies had established common data standards with collaboration partners in 2022.[12]
  • 67% of GCC chemical companies had established performance management or KPIs around digital supply chains in 2022.[12]
  • 28% of manufacturers had a data-governance leader in 2026, across the Manufacturing Leadership Council survey.[10]
  • 90% of supply-management organizations agreed or strongly agreed that data governance was necessary in 2024.[9]

KPIs in the biomaterials industry

  • 54% of Cabot’s critical suppliers were assessed for sustainability impacts in 2025.[13]
  • 97% of Corbion’s electricity was renewable in 2023, compared with 93% in 2022.[14]
  • 5.9% of Ingevity’s energy consumption came from renewable sources in 2024.[15]

06 Statistics

Strategy & Growth

Capacity and utilization benchmarks place bioplastics expansion in context, including 72% global utilization in bioplastics capacity in 2025.

Growth in the biomaterials industry

  • 132% is the projected increase in global bioplastics production capacity from approximately 2.47 million tonnes in 2024 to 5.73 million tonnes in 2029.[16]
  • 72% was the global average utilisation rate of bioplastics production capacity in 2025, with 1.67 million tonnes produced from 2.31 million tonnes of capacity.[16]
  • 10.3% of global bioplastics production capacity was allocated to automotive and transport applications in 2025, equal to 0.24 million tonnes.[16]
  • 41.3% of global bioplastics production capacity was allocated to packaging in 2025, equal to 0.95 million tonnes.[16]

Differentiation in the biomaterials industry

  • 37.1% was the estimated global bioplastics market share of polylactic acid in 2024, making PLA the leading bioplastic type identified in the study.[17]
  • 5.7% was the estimated global bioplastics market share of semi-synthetic cellulose polymer compounds in 2024.[17]
  • 4.6% was the estimated global bioplastics market share of PBAT in 2024.[17]

Mergers and acquisitions in the biomaterials industry

  • 1 acquisition transferred B. Braun’s global orthobiologics business, including NOVOCART, to Octane Medical in 2024.[18]
  • 1 acquisition of Noble Biomaterials by Americhem was announced in October 2026, adding antimicrobial and conductivity biomaterial technologies to Americhem’s portfolio.[19]
  • 1 acquisition expanded Geistlich Pharma’s regenerative-dentistry biomaterials portfolio when it bought Bionnovation Biomedical in Brazil in 2024.[20]
  • 1 acquisition of INNOTERE GmbH in 2025 helped Heraeus Medical establish a strategic business area for resorbable biomaterials.[21]
  • 1 acquisition agreement expanded RTI Surgical’s portfolio of engineered medical-grade collagen and xenograft biomaterials through its purchase of Collagen Solutions in 2024.[18]

Strategic partnerships in the biomaterials industry

  • 1 research partnership between BioMed X and AbbVie was extended in 2023 to focus on immunology and tissue engineering.[22]
  • 1 commercialization agreement between Celularity and BioCellgraft covered manufacture and distribution of advanced biomaterial products for oral healthcare in 2024.[23]
  • 1 distribution partnership between HVD Life Science and Poietis covered Poietis’ NGB-R platform in Australia and Germany in 2024.[22]
  • 1 strategic acquisition of Bionnovation Biomedical was described by Geistlich Pharma as part of a strategy combining in-house development, partnerships and acquisitions in regenerative medicine.[20]

07 Statistics

People & Workforce

Hybrid and on-site balance is visible in workforce statistics, including U.S. hybrid employees spending an average of 46% of the workweek on-site in 2026.

Remote Work in the chemicals and materials sector (sector benchmark)

  • Among U.S. energy, natural-resources and chemicals workers, 8% preferred fully remote work in 2025.[24]
  • Among U.S. energy, natural-resources and chemicals workers, 25% preferred mostly remote work in 2025.[24]
  • Across U.S. remote-capable employees, 25% worked exclusively remotely in August 2026.[25]
  • Across U.S. chemical and pharmaceutical manufacturing employers, 5.7% of positions were fully remote in 2024.[26]

Hybrid Work in the chemicals and materials sector (sector benchmark)

  • Across U.S. chemical and pharmaceutical manufacturing employers, 44.5% of positions were fully hybrid in 2024.[26]
  • Across U.S. remote-capable employees, 61% preferred a hybrid work arrangement in November 2025.[25]
  • Across U.S. hybrid employees, 48% said their team had not discussed a formal or informal collaboration plan in 2026.[25]
  • U.S. hybrid employees spent an average of 46% of their workweek on-site in 2026.[25]
  • Across U.S. remote-capable employees, 54% worked in a hybrid arrangement in August 2026.[25]

Employee Engagement in the chemicals and materials sector (sector benchmark)

  • Across employees in the United States, 32% were engaged at work in 2025.[25]
  • Among global managers, 22% were engaged at work in 2025, compared with 19% of non-managers.[25]
  • Across best-practice organizations recognized by Gallup, 70% of employees were engaged in 2025.[25]
  • Across employees worldwide, 20% were engaged at work in 2025.[25]
  • Across employees in the United States and Canada, 31% were engaged at work in 2025.[25]

Change Management in the chemicals and materials sector (sector benchmark)

  • Across leaders in the United States, United Kingdom, Australia and Canada, change management was associated with a reported 4:1 return on investment in 2026.[27]
  • Across organizations surveyed globally, 56% said they were succeeding at business outcomes during times of change in 2023.[28]
  • Across organizations surveyed globally, 60% said they were succeeding at business outcomes during times of change in 2024.[28]
  • Across leaders in the United States, United Kingdom, Australia and Canada, 73% reported employee change fatigue in 2026.[27]
  • Across organizations surveyed globally, 46% said they were succeeding at business outcomes during times of change in 2022.[28]

08 Statistics

Marketing & Brand

Influencer-program tactics remain a B2B marketing input, with 56% of marketers citing social-media posts as the most effective influencer-program content type in September 2024.

Influencer Marketing in the chemicals and materials sector (sector benchmark)

  • Across B2B companies, 56% of marketers identified social-media posts as the most effective influencer-program content type in a September 2024 U.S. survey.[29]
  • Across B2B companies, 29% of marketers planned to adopt influencer marketing within the following year in a March 2025 Ipsos survey.[30]
  • Across B2B companies, 43% of marketers reported outstanding results from influencer programs in the 2025 B2B Influencer Marketing Report.[31]
  • Across B2B companies, 55% of marketers used creators in 2025, based on a March 2025 Ipsos survey of 1,500 marketing professionals.[30]
  • Across B2B companies, 81% of marketers had a dedicated influencer-marketing budget in a September 2024 U.S. survey of firms with at least 100 employees.[29]

09 Statistics

Operations & Execution

Sourcing and production execution pressures surface through customer onshoring outcomes, including 50% pushing onshoring projects in 2025 with no success reported by customers.

Outsourcing / Offshoring in the chemicals and materials sector (sector benchmark)

  • Across North American specialty chemicals, 50% of customer respondents were actively pushing onshoring projects in 2025.[32]
  • Across North American specialty chemicals, 50% of customer respondents actively drove onshoring projects with suppliers but reported no success in 2025.[32]
  • Across North American specialty chemicals, 43% of customer respondents actively drove onshoring projects with suppliers and achieved some success in 2025.[32]
  • Across 22 EU countries and Norway, 72.8% of enterprises engaged in international sourcing moved business functions to other EU countries during 2021–2023.[33]
  • Across 22 EU countries and Norway, 34.1% of enterprises engaged in international sourcing cited labour-cost reduction as a motivation during 2021–2023.[33]

10 Statistics

Finance & Pricing

Earnings sensitivity is reflected in biomaterials-sector reporting, including a $276,000 gross profit decrease in the six months ended June 30, 2026 at a biomaterial-products company.

Profitability in the biomaterials industry

  • Gross profit at a biomaterial-products company decreased by $276,000 in the six months ended June 30, 2026, as lower-margin initial product sales, inventory write-offs, freight and royalties affected results.[34]
  • 9.8% was Valmet’s operating margin for its Biomaterial Solutions and Services segment in the second quarter of 2024, on segment revenue of €973 million.[35]

Financial planning in the biomaterials industry

  • 148,000-plus professionals made up the global biomaterials workforce in StartUs Insights’ 2025 industry database.[6]
  • $600 million was invested by ValueAct Capital in at least one biomaterials company, according to StartUs Insights’ 2025 industry database.[6]
  • More than 2,100 grants were recorded for the global biomaterials sector in StartUs Insights’ 2025 industry database.[6]
  • 11.98% was the annual growth rate of the biomaterials sector reported in StartUs Insights’ 2025 industry database.[6]

11 Statistics

Product & Service

Sustainability and lifecycle evidence show up in development work, including 1,683 life-cycle assessments completed by Amcor in fiscal 2023.

Product development in the biomaterials industry

  • 100% of Cabot’s new development projects had a sustainability benefit in 2025.[13]
  • 1,683 life-cycle assessments were completed by Amcor in fiscal 2023 to support development of more sustainable packaging solutions using biomaterials.[8]
  • 100% of Cabot’s new development projects were assessed for sustainability impacts in 2025.[13]

Product lifecycle in the biomaterials industry

  • 89% of Amcor’s flexible packaging portfolio had a recycle-ready solution available in fiscal 2023.[8]
  • 72.6% of Ingevity’s 2024 net sales were attributable to sustainable products supported by life-cycle analysis.[15]
  • 53.3% of Ingevity’s manufacturing volume was attributable to sustainable products in 2024.[15]
  • 95% of Amcor’s rigid packaging portfolio by weight was considered recyclable in practice and at scale in fiscal 2023.[8]

Value proposition in the biomaterials industry

  • 79% of Corbion’s total revenues contributed to the United Nations Sustainable Development Goals in 2025.[7]
  • Biomaterials-based companies generated roughly 99% of tissue-engineering product sales in the United States in the 2011–2018 study period.[22]
  • Corbion’s Biomaterials volume and mix grew by a mid-teen percentage in 2025, driven by drug delivery, orthopedics and aesthetics applications.[36]
  • €297.0 million was Corbion Health & Nutrition net sales in 2025, a segment that includes biomaterials.[36]

12 Statistics

Sustainability & Ethics

Supply-chain and operational emissions metrics are tracked, including 97% of Corbion’s electricity being renewable in 2023.

Sustainability in the biomaterials industry

  • 331,000 metric tons of biomaterials were purchased by Amcor in fiscal 2023.[8]
  • 79% of Corbion’s revenues contributed to the United Nations Sustainable Development Goals in 2025.[36]
  • The three main CovationBio product lines contain biobased material derived from annually renewable plant resources, according to its 2022 sustainability reporting.[37]

ESG in the biomaterials industry

  • 1.4 billion dollars was Ingevity’s 2024 net sales, of which 72.6% was attributable to sustainable products.[15]
  • 72.6% of Ingevity’s 2024 net sales were attributable to sustainable products.[15]

Ethics in the biomaterials industry

  • 39 biomaterials clinical trials were identified in a United States tissue-engineering review covering 2011–2018.[22]
  • 5.8% of the biomaterials companies catalogued by BIOMATDB served the veterinary sector in 2023.[38]
  • 90.4% of the 404 biomaterials companies catalogued by BIOMATDB served the human sector in 2023.[38]

CSR in the biomaterials industry

  • DSM Biomedical received a Platinum EcoVadis CSR rating in 2023, placing it in the top 1% of companies rated in its industry.[39]
  • CovationBio aligned its sustainability commitments with four United Nations Sustainable Development Goals in its first report published in 2023.[37]

Circular economy in the biomaterials industry

  • 200,000 metric tons of recycled content were purchased by Amcor in fiscal 2023.[8]
  • 143 Amcor sites held zero-waste-to-disposal certification in fiscal 2023.[8]
  • 4.00 metric tons of CO2e per metric ton of product was Cabot’s average portfolio product-carbon footprint in 2025.[13]

Carbon footprint in the biomaterials industry

  • 97% of Corbion’s electricity was renewable in 2023, supporting lower operational carbon emissions.[14]
  • 4.00 metric tons of CO2e per metric ton of product was Cabot’s average portfolio product-carbon footprint in 2025, 4.5% below its 2022 baseline.[13]
  • 5.9% of Ingevity’s energy consumption came from renewable sources in 2024, a metric used in its carbon-footprint management.[15]
  • 3.64 metric tons of CO2e per metric ton was Cabot’s 2025 average product-carbon footprint for furnace carbon black.[13]

14 Statistics

Globalization & Expansion

Production geography shifts are quantifiable, including 51.6% of global bioplastics production capacity located in Asia in 2024.

Globalization in the biomaterials industry

  • 51.6% of global bioplastics production capacity was located in Asia in 2024, compared with 28.1% in Europe and 13.3% in North America.[44]
  • 2.47 million tonnes was the projected global bioplastics production capacity for 2024, rising to approximately 5.73 million tonnes by 2029.[16]
  • 45% of global bioplastics capacity was allocated to packaging in 2024, equivalent to 1.12 million tonnes.[16]
  • 1.605 million tonnes of bioplastics production capacity was located in Asia in 2024, the largest regional total worldwide.[44]

Supplier management in the biomaterials industry

  • 44% of surveyed biomaterials suppliers described themselves as very familiar with biomaterials, while 22% identified as experts in the field.[38]
  • 56% of surveyed biomaterials suppliers were male and 44% were female in the BIOMATDB stakeholder survey.[38]

Stakeholder management in the biomaterials industry

  • 80% of surveyed biomaterials demanders considered themselves familiar with biomaterials, while 20% reported only limited or very limited knowledge.[38]
  • 60% of surveyed biomaterials demanders worked in the private sector and 40% worked in the public sector.[38]
  • 78% of surveyed biomaterials researchers worked in the public sector, while 80% of surveyed investors and policymakers worked in the private sector.[38]
  • 40% of surveyed biomaterials regulators and policymakers identified as female, 20% as male and 40% did not disclose gender.[38]

Distribution channels in the biomaterials industry

  • 1 U.S. medical distributor held a distribution and services agreement for BioStem Technologies’ Amnio Wrap 2 product in 2023, expanded to include VendajeAC in the fourth quarter of 2024.[34]
  • 45% of global bioplastics production capacity served packaging applications in 2024, making packaging the industry’s largest application channel.[16]
  • 1 commercialization agreement covered manufacture and distribution of Celularity’s advanced biomaterial products for oral healthcare through BioCellgraft in 2024.[23]

Key questions about the biomaterials industry

What is the biomaterials market size in 2026?
The global biomaterials market is estimated at $274.6 billion in 2026, according to Grand View Research.
How fast is the biomaterials market expected to grow after 2026?
Grand View Research forecasts the market to reach $836.5 billion by 2033, implying a 17.3% CAGR from 2026 to 2033.
Which companies lead the biomaterials industry?
NatureWorks stands out for Ingeo PLA biopolymers for packaging and fibers because it manufactures Ingeo PLA biopolymers for packaging and fibers, while Novamont focuses on MATER-BI compostable bioplastics since it is a recognized producer of MATER-BI compostable bioplastics.
What technology shift shows up in biomaterials digital and analytics activity?
Among EII businesses, 68% reported adopting AI in 2024 with an estimated 10% productivity increase.
What does market structure look like for biomaterials suppliers and buyers?
No reliable public source provides a standardized global concentration ratio for leading biomaterials companies, and the market includes specialist biomaterial manufacturers alongside medical-device and coatings suppliers.
How is biocompatibility risk assessed for biomaterials in medical devices in the U.S.?
The FDA evaluates biocompatibility of the finished medical device and its materials, processing, sterilization, contact type, and exposure duration, with September 2023 guidance using risk-based assessment for absorbable and nanotechnology-containing materials.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 11). Biomaterials Industry Statistics. Gitnux. https://gitnux.org/biomaterials-industry-statistics
MLA
Samuel Norberg. "Biomaterials Industry Statistics." Gitnux, 11 Nov 2026, https://gitnux.org/biomaterials-industry-statistics.
Chicago
Samuel Norberg. 2026. "Biomaterials Industry Statistics." Gitnux. https://gitnux.org/biomaterials-industry-statistics.

Sources & references

57 sources cited across this report

  1. monitor-industrial-ecosystems.ec.europa.eu
  2. s3.us-east-1.amazonaws.com
  3. ibm.com
  4. cefic.org
  5. oecd.org
  6. startus-insights.com
  7. corbion.com
  8. assets.ctfassets.net
  9. utah.ismworld.org
  10. manufacturingleadershipcouncil.com
  11. dnb.com
  12. gpca.org.ae
  13. cabotcorp.com
  14. financialfilings.com
  15. ingevity.com
  16. european-bioplastics.org
  17. doi.org
  18. globenewswire.com
  19. americhem.com
  20. geistlich.com
  21. heraeus-medical.com
  22. pmc.ncbi.nlm.nih.gov
  23. celularity.com
  24. kpmg.com
  25. gallup.com
  26. naceweb.org
  27. deloitte.com
  28. sia-partners.com
  29. marketingprofs.com
  30. business.linkedin.com
  31. toprankmarketing.com
  32. 5418442.fs1.hubspotusercontent-na1.net
  33. ec.europa.eu
  34. sec.gov
  35. biomaterials.org
  36. annualreport.corbion.com
  37. covationbio.com
  38. biomatdb.eu
  39. dsm-firmenich.com
  40. enhesa.com
  41. ismg-cdn.nyc3.cdn.digitaloceanspaces.com
  42. trustarc.com
  43. chemtrec.com
  44. ifbb-hannover.de
  45. grandviewresearch.com
  46. straitsresearch.com
  47. orthoworld.com
  48. fda.gov
  49. natureworksllc.com
  50. mdpi.com
  51. cjbiomaterials.com
  52. thebusinessresearchcompany.com
  53. covestro.com
  54. who.int
  55. pubmed.ncbi.nlm.nih.gov
  56. tandfonline.com
  57. lsc-pagepro.mydigitalpublication.com